Daniel Shapiro, MD, FACS

Daniel Shapiro, MD, is an assistant professor with the Departments of Urology and Radiology. Dr. Shapiro earned his undergraduate and medical degrees at the University of Wisconsin-Madison. After a five-year residency, also at UW-Madison, he completed a two-year fellowship at MD Anderson Cancer Center in Houston, TX, the largest cancer center in the United States.

Inspired by the mentorship and training he received while at UW-Madison, Dr. Shapiro chose to return so that he could “pay that forward and help train future urologists.” Continuing the research he began in his residency, he has focused on prognostic factors for patients undergoing removal of a kidney. Dr. Shapiro’s goal is to refine how urologists decide which patients should receive surgery. Ultimately, he seeks to optimize the management of kidney cancers in order to minimize the morbidity of treatment and prolong life expectancy.

Dr. Shapiro’s clinical specialties include a breadth of urologic malignancies, covering cancers that affect the kidney, bladder, prostate, and testis. He specializes in both open and complex surgeries as well as minimally invasive procedures using robotics and laparoscopic techniques.

Education

• Fellowship, Urologic Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX
• Internship and Residency, University of Wisconsin Hospitals and Clinics, Madison, WI
• MD, University of Wisconsin School of Medicine and Public Health, Madison, WI
• BS, Medical Microbiology and Immunology, University of Wisconsin – Madison, Madison, WI

Clinical Specialties

Dr. Shapiro has fellowship training in diagnosis and management of all urologic malignancies. His fellowship included advanced training in open, laparoscopic, and robotic surgery for kidney cancer, bladder cancer, prostate cancer, testis cancer, adrenal cancer, and penile cancer. Dr. Shapiro incorporates multidisciplinary care to treat urologic cancers and improve patient quality of life.

Research Interests

Dr. Shapiro conducts clinical and translational research. He is interested in how the kidney tumor microenvironment influences tumor behavior and how this information can be applied clinically. He is investigating how the spatial immune phenotype of kidney cancer can predict cancer specific outcomes. Additionally, he performs clinical research evaluating urologic cancer outcomes after surgical intervention. He also has a special interest in rare forms of kidney cancer and how to improve their diagnosis and treatment. His research on renal medullary carcinoma was selected for a scholar-in-training award by the American Academy of Cancer Research. Dr. Shapiro has published numerous research studies and abstracts on these topics.